NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for ...

The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's blood ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

The European Medicines Agency (EMA) has recommended extending the use of Mounjaro to younger patients with diabetes, ...

PureHealth Research today announced the launch of its new line of vein health supplements, offering a natural approach to supporting healthy circulation and promoting the appearance of ...

The Institute for Advanced Reconstruction (IFAR) and The Plastic Surgery Center (TPSC) today announced the opening of a new 6,800-square-foot facility in Glen Rock, N.J., just 20 miles northwest of ...

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.